From the concentrations of cytokines measured, we confirmed that SGD treatment significantly elevated IL-13 in MCAO rats, which was likely to activate the downstream JAK2-STAT6 signaling pathway to mediate the beneficial effects. The gene discussed is JAK2; the disease is specific granule deficiency.